Document 0779
 DOCN  M9470779
 TI    [Antiviral treatment of HIV infection]
 DT    9409
 AU    Gerstoft J; Pedersen C; Mathiesen LR; Frederiksberg Hospital, medicinsk
       afdeling B.
 SO    Ugeskr Laeger. 1994 Apr 25;156(17):2555-6, 2559-60, 2563-5. Unique
       Identifier : AIDSLINE MED/94287557
 AB    During the past six years Zidovudine has been the main antiviral drug
       directed against HIV. The indications for its use have slowly been
       extended and a reduced dose has limited the side effects. The
       therapeutical gain is a survival benefit of three to nine months. Other
       nucleoside analogues such as didanosin and zalcitabin have shown
       antiviral efficacy but the side effects are different from those of
       zidovudine. A number of drugs, including protease inhibitors and
       non-nucleoside reverse transcriptase inhibitors have shown antiviral
       effects, and are being tested in clinical trials. As no single drug
       appears to be able to control HIV for an extended period of time,
       combination regimens including multiple drugs, often administered early
       in the course of infection, seem to be a promising approaches, which are
       being pursued in a number of clinical trials.
 DE    Antiviral Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Drug Therapy,
       Combination  English Abstract  Human  HIV Infections/*DRUG THERAPY
       Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).